Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor–treated CML stem cells-Reference-Cited by-同舟云学术

Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor–treated CML stem cells

Published:2016-12-08 Issue:23 Volume:128 Page:2671-2682
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Zhang Bin¹,Chu Su²,Agarwal Puneet²,Campbell Victoria L.³,Hopcroft Lisa³,Jørgensen Heather G.³,Lin Allen¹,Gaal Karl⁴,Holyoake Tessa L.³,Bhatia Ravi²

Affiliation:

1. Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope National Medical Center, Duarte, CA;

2. Division of Hematology-Oncology, University of Alabama at Birmingham, Birmingham, AL;

3. College of Medical, Veterinary, & Life Sciences, Institute of Cancer Sciences, University of Glasgow, United Kingdom; and

4. Department of Pathology, City of Hope National Medical Center, Duarte, CA

Abstract

Key Points CML LSC demonstrate increased IL-1 receptor expression and enhanced signaling response. Inhibition of IL-1 signaling using the antagonist IL-1RA enhances targeting of CML LSC in combination with TKI.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/128/23/2671/1396877/blood679928.pdf

Reference32 articles.

1. Chronic myeloid leukemia;Sawyers;N Engl J Med,1999

2. Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia;Cortes;J Clin Oncol,2011

3. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment;Chu;Blood,2011

4. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial;Mahon;Lancet Oncol,2010

5. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study;Ross;Blood,2013

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multi-Walled Carbon Nanotubes Accelerate Leukaemia Development in a Mouse Model;Toxics;2024-09-02

2. IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells;Journal of Hematology & Oncology;2024-08-14

3. IL-1 in aging and pathologies of hematopoietic stem cells;Blood;2024-07-25

4. Deregulation of New Cell Death Mechanisms in Leukemia;Cancers;2024-04-25

5. Autophagy prevents graft failure during murine graft-versus-host disease;Blood Advances;2024-04-23